Therapeutic potential of protein and adjuvant vaccinations on tumour growth

C. M. Gérard, N. Baudson, K. Kraemer, C. Bruck, N. Garçon, Y. Paterson, Z. K. Pan, D. Pardoll

Research output: Contribution to journalArticlepeer-review


Over 90% of cervical cancers are associated with HPV infection, the commonest being the HPV-16 subtype. Two early viral genes, E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing tumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)2583-2589
Number of pages7
Issue number17-19
StatePublished - Mar 21 2001


  • Adjuvants
  • Cancer immunotherapy
  • HPV E7 protein

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Therapeutic potential of protein and adjuvant vaccinations on tumour growth'. Together they form a unique fingerprint.

Cite this